PharmaResearch Completes Successful REJURAN Presentation Tour Across Western Europe

PharmaResearch Co., Ltd., a South Korean company specializing in regenerative medicine, has concluded a successful presentation tour for its innovative skin booster, REJURAN, across five key markets in Western Europe. This tour was an essential part of its gradual expansion strategy throughout the region, bringing significant attention to their advanced skin treatment methods.

The tour commenced with a symposium held in the Benelux region on April 22 and 23, followed by engagements in the United Kingdom on April 28 and Switzerland on April 30. These events attracted healthcare professionals from across the participating markets, allowing PharmaResearch to showcase its proprietary 'DNA Optimizing Technology (DOT™)' and highlight various clinical applications.

During the symposium, several key opinion leaders (KOLs) presented detailed clinical results, existing treatment protocols, and real-world case examples related to the REJURAN product line. The sessions covered a wide array of products within the REJURAN portfolio, tailored to various skin concerns ranging from general facial enhancement to targeted treatments for finer skin areas like the eye contours and for conditions such as wrinkles and scars.

The pharmaceutical firm observed a growing interest from attendees who engaged in detailed inquiries about the product specifics and practical usage scenarios. According to Vera Tual, customer care director at VIVACY, the European partner of PharmaResearch, the enthusiasm displayed by healthcare professionals markedly reflects REJURAN's solid reputation in Asia, which appears to be generating a significant initial momentum in Europe as well.

PharmaResearch has already made significant strides with its operations, having completed its first shipment to the European market back in January. In anticipation of the positive feedback received, the company is actively expanding its product offerings and enhancing its clinical training programs across Europe to further solidify its market position.

The next phases in the expansion plan include continuing the educational tour with upcoming events scheduled for Italy in May, Poland in June, and France in September. Moreover, plans to venture into the German market and other European countries are also underway in the latter half of the year. This gradual yet strategic rollout not only aims to build brand awareness but also to establish a comprehensive distribution network throughout Europe.

A representative from PharmaResearch underlined the promising growth of interest surrounding PN-based injectables in Europe, despite the market being in its infancy stage. They are confident that this is the ideal moment for the introduction of REJURAN as a credible skin booster, augmented by the credibility of their DOT™ technology and clinical expertise.

Positive initial reactions have led PharmaResearch to revise its internal targets upwards, reinforcing the commitment to enhance distribution networks and clinical training programs across Europe. The alignment with local partners will be critical in realizing their ambitious plans and ensuring the successful integration of REJURAN into the European skincare market.

PharmaResearch continues to dedicate itself to improving the quality of life through innovative regenerative medical solutions. With its headquarters in Gangneung-si, Gangwon-do, South Korea, and a U.S. subsidiary located in Costa Mesa, California, the company is well-positioned to leverage both its technological advancements and global partnerships to drive its mission forward.

For further insights into PharmaResearch's initiatives, please visit PharmaResearch's official site.